多模态深度学习
Search documents
中山大学×郑州大学合作Cell子刊:利用多模态AI模型,支持食管癌个性化治疗决策
生物世界· 2025-12-09 08:18
Core Viewpoint - The article discusses the development of a multimodal AI model named eSPARK, which aims to enhance personalized treatment decisions for esophageal cancer, particularly esophageal squamous cell carcinoma (ESCC) [4][9]. Group 1: Background and Importance - Esophageal cancer (EC) is a common malignant tumor and the seventh leading cause of cancer-related deaths, with ESCC accounting for approximately 80% of cases [2]. - The prognosis for ESCC is poor, primarily due to late-stage diagnosis, and traditional surgical interventions have limited effectiveness for advanced cases [2][3]. Group 2: New Treatment Approaches - Neoadjuvant immunochemotherapy (nICT) has emerged as a promising treatment for esophageal cancer, but it only achieves optimal results in 20%-40% of patients, highlighting the need for reliable biomarkers to predict treatment response [3][6]. - The urgency to identify biomarkers is driven by the potential for improving patient outcomes and reducing unnecessary toxic side effects associated with over-treatment [3]. Group 3: Research Development - The study published in Cell Reports Medicine introduces the eSPARK model, which integrates multimodal deep learning to enhance predictive performance for nICT efficacy in ESCC [4][6]. - The model utilizes data from 344 patients, incorporating pre-treatment CT images and pathology slides, along with post-operative pathological complete response (pCR) outcomes [7]. Group 4: Key Findings - eSPARK demonstrates superior generalization capabilities compared to unimodal models and achieves robust predictive accuracy across multicenter datasets [7]. - The model identifies several biomarkers related to nICT treatment response, including the neutrophil-to-lymphocyte ratio (NLR), where a lower NLR may indicate better treatment response [7][9]. - The research emphasizes the potential of eSPARK in personalized treatment decision-making for locally advanced esophageal cancer and its broader implications for precision oncology through multidisciplinary data integration [9].